NASDAQ:UTHR United Therapeutics Q3 2025 Earnings Report $418.58 -7.63 (-1.79%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$419.62 +1.04 (+0.25%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast United Therapeutics EPS ResultsActual EPSN/AConsensus EPS $6.75Beat/MissN/AOne Year Ago EPSN/AUnited Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$812.87 millionBeat/MissN/AYoY Revenue GrowthN/AUnited Therapeutics Announcement DetailsQuarterQ3 2025Date10/29/2025TimeBefore Market OpensConference Call DateWednesday, October 29, 2025Conference Call Time9:00AM ETConference Call ResourcesEarnings HistoryCompany Profile United Therapeutics Earnings HeadlinesUnited Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from Brokerages5 hours ago | americanbankingnews.comIf You Invested $100 In United Therapeutics Stock 15 Years Ago, You Would Have This Much TodayOctober 21, 2025 | benzinga.comNvidia CEO’s Regret: ‘I Wish I Gave [Elon] More’…Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Since then, we've seen a massive rollout of AI legislation, and the some of the stocks I recommended back then have doubled the market's return. Now I'm releasing a new "BUY LIST" to take advantage of Elon’s next launch, and giving away one name and ticker for free on this page here. | Altimetry (Ad)Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent CaseOctober 16, 2025 | insidermonkey.comUnited Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025October 15, 2025 | finance.yahoo.comUnited Therapeutics to Feature Clinical Data at the CHEST 2025 Annual MeetingOctober 13, 2025 | finance.yahoo.comSee More United Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like United Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on United Therapeutics and other key companies, straight to your email. Email Address About United TherapeuticsUnited Therapeutics (NASDAQ:UTHR) (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs. In addition to its PAH portfolio, United Therapeutics markets dinutuximab (Unituxin) for high-risk neuroblastoma and continues to expand its therapeutic reach through ongoing clinical programs. Founded in 1996 and headquartered in Silver Spring, Maryland, United Therapeutics has combined its core expertise in vascular biology with innovative manufacturing technologies. Beyond pharmaceuticals, the company’s Lung Biotechnology PBC subsidiary explores regenerative medicine approaches, including decellularized and recellularized organ scaffolds and xenotransplantation methods aimed at addressing organ shortages. Its research pipeline encompasses next-generation agents for PAH, oncology, and transplant applications, reflecting a broad commitment to extending and improving life for patients with complex diseases. United Therapeutics operates globally, with commercial and clinical efforts spanning North America, Europe, and Asia. Its international infrastructure supports regulatory submissions and patient access programs in key markets such as the European Union and Japan. Under the leadership of founder and Chief Executive Officer Martine Rothblatt, the company emphasizes a multidisciplinary culture that integrates basic science, engineering and patient advocacy. This approach drives its mission to pioneer transformational therapies and sustainable organ manufacturing technologies for conditions with high unmet medical need.View United Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)American Tower (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
